Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation

Conclusions The results show that dabigatran is a dominant alternative, i.e., it produces better clinical results at a lower cost. Sensitivity analysis demonstrates that the results are robust even considering the uncertainty inherent in an indirect comparison. It can thus be concluded that in clinical practice in Portugal the use of dabigatran is to be preferred to the use of rivaroxaban.
Source: Revista Portuguesa de Cardiologia - Category: Cardiology Source Type: research